Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Role of p-glycoprotein in the brain penetration and brain pharmacodynamic activity of the mek inhibitor cobimetinib

  • At: 2014 FIP Congress in PSWC, Melbourne (Australia)
  • Type: Poster
  • By: CHOO, Edna (Genentech Inc., Drug Metabolism and Pharmacokinetics, South san francisco, United States of America)
  • Co-author(s): Ly, Justin (Genentech Inc., South san francisco, United States of America)
    Chan, Jocelyn (Genentech Inc., South san francisco, United States of America)
    Shahidi-Latham, Sheerin (Genentech Inc., South san francisco, United States of America)
    Messick, Kirsten (Genentech Inc., South san francisco, United States of America)
    Plise, Emile (Genentech Inc., South san francisco, United States of America)
    Quiason, Cristine (Genentech Inc., South san francisco, United States of America)
    Yang, Lulu (Genentech Inc., South san francisco, United States of America)
  • Abstract:

    Background: Cobimetinib is a small molecule MEK inhibitor currently being tested in multiple combinations, including a phase 3 clinical trial in combination with vemurafenib, in patients with metastatic melanoma.
    Aims: The study were conducted to determine whether cobimetinib is a substrate of P-glycoprotein (P-gp) and breast cancer resistance..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses